Guidelines on the treatment of primary immune thrombocytopenia in children and adolescents: Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associacao Medica Brasileira - 2012 by Loggetto, Sandra Regina et al.
Special Article
417Rev Bras Hematol Hemoter. 2013;35(6):417-27
Guidelines on the treatment of primary immune thrombocytopenia in children and 
adolescents: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular
Guidelines Project: Associação Médica Brasileira – 2012
Sandra Regina Loggetto1
Josefina Aparecida Pellegrini Braga2
Mônica Pinheiro de Almeida Veríssimo3
Wanderley Marques Bernardo4,5
Leticia Medeiros6
Andrea Thives de Carvalho Hoepers7,8
1Centro de Hematologia de São Paulo – 
CHSP, São Paulo, SP, Brazil
2Escola Paulista de Medicina da Universidade 
Federal de São Paulo – UNIFESP, São Paulo, 
SP, Brazil
3Centro Infantil Boldrini, Campinas, SP, Brazil
4Faculdade de Medicina da Universidade de 
São Paulo – USP, São Paulo, Brazil
5Associação Médica Brasileira – AMB, São 
Paulo, Brazil
6Hospital Ana Costa – HAC, Santos, SP, Brazil
7Centro de Hematologia e Hemoterapia de 
Santa Catarina – HEMOSC, Florianópolis, 
SC, Brazil
8Universidade Federal de Santa Catarina – 
UFSC, Florianópolis, SC, Brazil
Conflict-of-interest disclosure:
The authors declare no competing financial 
interest
Submitted: 10/11/2013
Accepted: 10/16/2013
Corresponding author:
Sandra Regina Loggetto
Centro de Hematologia de São Paulo - CHSP
Av Brigadeiro Luiz Antonio 2533 - Jardim 
Paulista
01401-000 São Paulo, SP, Brazil
loggetto.sr@hotmail.com
www.rbhh.org or www.scielo.br/rbhh
DOI: 10.5581/1516-8484.20130124
Introduction
The guidelines project is a joint initiative of the Associação Médica Brasileira and 
the Conselho Federal de Medicina. It aims to bring information together to standardize 
decisions in order to help strategies during diagnosis and treatment. The data contained 
in this manuscript were prepared by and recommended by the Associação Brasileira de 
Hematologia, Hemoterapia e Terapia Celular (ABHH). Even so, all possible decisions on 
diagnosis and treatment should be evaluated by the physician responsible according to the 
patient’s setting and clinical status.
Aim
To define parameters for the treatment of children and adolescents with ITP based on the 
best available published evidence. The target audience is the hematologist, pediatrician and 
medical student.
Description of the evidence collection method
The members of the ABHH Committee responsible for writing the treatment 
guidelines on primary immune thrombocytopenia (ITP) prepared the main questions on 
treatment of children and adolescents. Nine questions were structured using the Patient/
Problem, Intervention, Comparison and Outcome (PICO) system. The search strategies for 
specific clinical questions were applied to the key scientific databases (MEDLINE PubMed, 
Embase, SciELO, Lilacs and Cochrane Library) for publications up to 2012. The retrieved 
articles were submitted to a critical appraisal and categorized according to the strength of 
evidence, giving support to elaborate the answers to the questions. Each selected reference 
was classified according to the degree of recommendation using the Oxford Classification(1). 
Each recommendation was discussed by the committee and a consensus was attained. The 
development of these recommendations was completely supervised by experts on evidence-
based guidelines.
Recommendation degree and evidence level
A: Major experimental or observational studies 
B: Minor experimental or observational studies 
C: Case reports (uncontrolled studies)
D: Opinion without critical evaluation based on consensus, physiological studies or 
animal models
Background
Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disease where 
the platelet count is < 100 x 109/L. Nowadays the immune etiology is well known and not 
every patient suffers from bleeding and so the terms ‘idiopathic’ and ‘purpura’ should be 
avoided(2)(D). Secondary ITP involves immune-mediated forms of thrombocytopenia, such as 
systemic lupus erythematosus, human immunodeficiency virus (HIV), hepatitis C, drugs, and 
Helicobacter pylori, among others(2-4)(D).
Older publications, published before the introduction of the current terminology 
were used to write these guidelines. Thus, for older studies, acute ITP and chronic ITP 
are used for cases with up to six months and more than six months of thrombocytopenia, 
respectively.
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What is the correct approach to treat patients with 
newly diagnosed primary immune thrombocytopenia 
and active bleeding?
Prospective randomized trials have been performed to 
evaluate the treatment of children with newly diagnosed ITP 
with platelet counts < 20 x 109/L. More favorable results were 
obtained with the administration of a single dose of intravenous 
immunoglobulin (IVIg - 0.8 g/kg) compared to IVIg (1 g/kg/day) 
for two consecutive days, anti-D immunoglobulin (anti-D - 25 
mg/kg/day) for two days or oral prednisone (4 mg/kg) for 21 days 
in 146 pediatric patients aged six months to 18 years old. Anemia 
was an adverse event related to anti-D administration(5)(A).
Single doses of anti-D (50 mg/kg), anti-D (75 mg/kg) or 
IVIg (0.8 g/kg) were compared in 105 children. After 24 hours of 
treatment, 50%, 72% and 77% of the patients from the anti-D50, 
anti-D75 and IVIg arms, respectively, achieved platelet counts > 
20 x 109/L (p-value = 0.03), suggesting that IVIg and the higher 
dose of anti-D are effective. However, a significant decrease in 
the hemoglobin level was observed in the anti-D groups(6)(A).
Another study with 81 children (six months to 14 years 
old) randomized to receive a single dose of anti-D (75 mg/kg) 
or IVIg (1 g/kg/day) for two consecutive days showed a higher 
response rate for the IVIg arm (98%) compared to the anti-D arm 
(76%: p-value = 0.017). After seven days, the platelet count was 
above 20 x 109/L in all patients who had received IVIg, while 
12% of the anti-D arm had platelet counts < 20 x 109/L. These 
findings show that the initial treatment of newly diagnosed ITP 
with IVIg increased the platelet count faster than anti-D(7)(A).
In a study with 25 children aged six months to 14 years old 
randomized to receive a single dose of anti-D (50 mg/kg) or IVIg 
(0.8 to 1 g/kg), the therapeutic response in 24 hours with both 
medications was effective to increase the platelet count above 20 
x 109/L. There was a decrease in the hemoglobin level with anti-D. 
Anti-D can be used only in non-splenectomized Rh-positive 
patients with a negative direct antiglobulin test (Coombs)(8)(B).
A retrospective analysis of 53 children with newly diagnosed 
ITP showed that purpura and mucosal bleeding (mean platelet count 
of 5 x 109/L) are associated with greater risk of treatment failure 
with IVIg or anti-D when compared to cases of purpura with bruises 
and/or petechiae with mean platelet counts of 10 x 109/L(9)(B).
An analysis of different treatments in children with newly 
diagnosed ITP and moderate bleeding found that IVIg was used 
in 24% of cases, corticosteroids in 27%, anti-D in 6%, combined 
therapy in 32% and no therapy in 11%. About 1.7% of these children 
developed, regardless of the treatment, severe bleeding. Of the 
children with platelet counts ≤ 20 x 109/L and no signs of bleeding or 
mild bleeding at diagnosis, three (0.6%) developed severe bleeding 
within 30 days. There was a statistically significant difference 
(p-value < 0.001) between the platelet count and the treatment chosen 
(conservative or drug treatment) in patients with no or mild bleeding. 
The mean platelet counts of patients who received no treatment, 
anti-D, IVIg, corticosteroids or combined therapy were 28 x 109/L, 
7 x 109/L, 9 x 109/L, 12 x 109/L and 8 x 109/L, respectively.(10)(B). 
Of newly diagnosed ITP patients who had suffered intracranial 
hemorrhage, 70% were receiving or had received treatment with 
corticosteroids and 13.6% of these had performed splenectomies(11)(B).
Splenectomy in the acute phase of ITP is rare. Of 134 under 
18-year-old splenectomized patients with ITP, only 21 (15%) 
had acute ITP (thrombocytopenia < 6 months); the median time 
between diagnosis and splenectomy was 4.1 months (0.7-5.9 
months)(12)(B).
Recommendation: The first line therapy for newly diagnosed 
ITP patients with platelet counts usually < 20 x 109/L and active 
bleeding are IVIg, corticosteroids or anti-D. Anti-D can only be 
used in non-splenectomized Rh-positive patients with a negative 
direct antiglobulin test (Coombs). Intracranial hemorrhage can 
occur even during treatment. Splenectomy may be indicated when 
there is no response to corticosteroids or immunoglobulins and the 
patient maintains bleeding, including of the central nervous system.
Is there evidence that the parenteral administration of 
high-dose methylprednisolone is faster and/or more 
effective than oral corticosteroid therapy?
A trial with 49 children with newly diagnosed ITP (platelet 
count < 50 x 109/L and < 7 days of disease) comparing oral prednisone 
(n = 16; 2 mg/kg/day for two weeks), parenteral administration of 
high-dose methylprednisolone (n = 16; 30 mg/kg/day for three 
days; 20 mg/kg/day for four days and subsequent reduction with 
10, 5, 2 and 1 mg/kg/day for seven days each) and wait and watch 
(n = 17) showed platelet response in three days in 69% of patients in 
the high-dose methylprednisolone arm, compared to 2-4 weeks in 
the oral prednisone arm. In the conservative treatment arm, 29.4% 
presented spontaneous remission in up to 15 days and 70.6% in up 
to four weeks. Treatment response in the first and second weeks 
was significant only for the high-dose methylprednisolone arm 
(p-value < 0.01) and similar between both oral prednisone and 
conservative treatment arms(13)(C).
A prospective study in Japan of 184 children aged one month 
to 14 years (median four years) with acute ITP (< 6 months of 
thrombocytopenia) without prior treatment, divided the patients into 
three groups. The group with platelet counts of less than 10 x 109/L 
or with platelet counts between 10 x 109/L and 29 x 109/L and active 
bleeding received IVIg (n = 32) or oral prednisolone (2 mg/kg/day 
- maximum dose 60 mg/day) for two weeks and subsequent dose 
reduction until day 21 (n = 29), or intravenous methylprednisolone 
(5 mg/kg/day) for five days (n = 31) or parenteral administration 
of high-dose methylprednisolone (30 mg/kg/day - maximum dose 
1000 mg/day) for three days (n = 27; pulse therapy). The time to 
achieve platelet counts above 30 x 109/L was similar (median three 
days) between intravenous methylprednisolone, pulse therapy and 
oral prednisone. The necessity of retreatment in 14 days was lower 
for those who received intravenous methylprednisolone or pulse 
therapy when compared to oral prednisone(14)(B).
Recommendation: Intravenous methylprednisolone may be 
effective in children with ITP when it is necessary to increase the 
platelet count rapidly.
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pain, striae distensae, hirsutism, acne, weight gain, myalgia, edema, 
nausea, vomiting, insomnia, anxiety and depression.
Recommendation: In children with chronic ITP, dexamethasone 
at 20-40 mg/m2 per day - maximum 40 mg/day - for four days 
every 15-28 days for 4-6 cycles is effective and suitable regarding 
the immediate response and may be a therapeutic option before 
recommending splenectomy.
What is the role of splenectomy in the treatment of 
primary immune thrombocytopenia in childhood/
adolescence?
Twenty-three splenectomized children with chronic ITP 
(persistent thrombocytopenia for at least three months) aged between 
3 and 17 years old (mean 11.7 ± 1.0 years) had presented clinical 
signs and symptoms, such as purpura (78%), petechiae (61%), 
epistaxis (43%), gingival bleeding (30%) and gastrointestinal 
bleeding (4%) at diagnosis. Prior to splenectomy, patients received 
a single course (four cases) or multiple courses of IVIg (19 cases); 
seven patients had poor responses to initial treatment with high 
doses of IVIg, four patients had good responses and 12 cases 
had excellent responses. Poor, good or excellent hematological 
responses were defined as platelet counts < 50 x109/L, between 50 
x 109/L and 150 x 109/L and ≥ 150 x109/L, respectively. Response 
to splenectomy was observed in 90% of the children who initially 
presented responses to IVIg, while if the response to IVIg was 
poor, response to splenectomy was only 43%. So excellent or good 
responses to IVIg can predict favorable responses to splenectomy 
and even children who do not respond to IVIg can be submitted to 
splenectomy when necessary(20)(B).
Under 16-year-old patients with chronic ITP (platelet 
count < 100 x 109/L, normal or increased megakaryopoiesis in 
bone marrow and thrombocytopenia > 6 months), who were 
initially treated with corticosteroids (33%), repeated courses of 
IVIg (29%), corticosteroid and IVIg (7%) or no drug treatment 
(31%), may require splenectomies (39%). The indications for 
splenectomy were resistance to oral prednisone (2 mg/kg/day) 
after six months of treatment and corticosteroid dependence 
(prednisone > 0.1 mg/kg/day). Before 1996, the indication for 
splenectomy was persistent platelet count < 30 x 109/L with 
recurrent episodes of bleeding or persistent platelet count < 10 x 
109/L without bleeding for more than six months. Since 1996 it 
has been proposed that only cases with recurrent severe bleeding 
that are not responsive to immunomodulatory during therapy for 
more than one year are splenectomized. Before splenectomy, all 
patients had recurrent bleeding episodes. One study followed up 
splenectomized patients for five to 16 years; 45% remained with 
complete response (platelet count > 100 x 109/L without treatment 
for at least two months) and 35% remained with partial response 
(platelet count > 30 x 109/L without treatment for at least two 
months). In patients for whom splenectomy failed (platelet count 
< 30 x 109/L and recurrent bleeding with or without therapy), 85% 
had been resistant to previous treatment with corticosteroids. 
Fifty percent of patients with complete response to splenectomy 
Is dexamethasone pulse therapy better than prednisone?
There are no pediatric studies comparing the response 
between dexamethasone pulse therapy and oral prednisone in the 
treatment of newly diagnosed or chronic ITP. Studies have been 
published comparing different doses of prednisone/prednisolone 
with a placebo. Most articles published on treatment of acute and 
chronic ITP patients using dexamethasone had small sample sizes.
High-dose oral dexamethasone (20 mg/m2/day for four 
days every 28 days for six cycles) was used in 17 children with 
symptomatic chronic ITP (> 6 months of thrombocytopenia) 
with platelet counts < 20 x 109/L. All had been treated with 
prednisone; other treatments included IVIg, anti-D, high-dose 
methylprednisolone and splenectomy. Thirty days after the last 
cycle, 35% of patients had normal platelet counts and, after one 
year, 29% maintained normal platelet counts. No patient diagnosed 
more than 30 months prior to this treatment had remission. The use 
of dexamethasone did not provide a uniform response, but it can 
be considered in the treatment of symptomatic chronic ITP(15)(C).
In two trials on chronic ITP refractory to previous treatment 
(prednisone, IVIg, anti-D or splenectomy) with platelet counts 
of less than 20 x 109/L, patients received high doses of oral 
dexamethasone (40 mg/m2/day for four days every 28 days for six 
cycles). After 72 hours, the platelet count was more than 100 x 109/L 
in 78% of the cycles (study with 11 children)(3)(C), and the median 
platelet count on Day 4 of treatment was 158 x 109/L (study with 
13 children)(4)(C). Disease duration did not interfere in the result(4)
(C). High-dose dexamethasone was effective in achieving response 
in chronic ITP and may be an option before splenectomy(16,17)(C).
High dose oral or intravenous dexamethasone (40 mg/day for 
over 15-year-old patients and 20 mg/m2 in children under 15 years 
old - maximum dose 40 mg/day for four days every 14 days for 
four cycles) was administered in 42 children aged two to 17 years 
old, with newly diagnosed ITP and platelet counts less than 30 x 
109/L or more than 30 x 109/L associated with active bleeding and 
no previous treatment. The median platelet count before treatment 
was 8 x 109/L. The overall response rate was 85.7%; 67% achieved 
platelet counts > 50 x 109/L at the end of the first cycle. The relapse-
free survival at 15 months was 96% [95% confidence interval (95% 
CI): 88.8-100.0] and long-term response in a median follow-up of 
eight months (range: 4-24 months) was 97.2%. The relapse rate 
after a median of 6.5 months (range: 3-10 months) after response 
to high-dose dexamethasone was 2.7%(18)(B).
High-dose intravenous dexamethasone (20 mg/m2/day - 
maximum 40 mg/day for four days every 15 days for four cycles) 
resulted in response in 83.6% of the cases of chronic ITP (more 
than six months of thrombocytopenia and platelet count < 10 x 
109/L with bleeding) in 12 under 18-year-old children. Complete 
response (platelet count > 150 x 109/L) occurred in 66.6%, partial 
response (platelet count 50 to 150 x 109/L) in 17% and treatment 
failure (platelet count < 20 x 109/L) in 17%. Of these patients, 
40% responded after the second cycle, 20% after the third cycle 
and 40% after the fourth cycle. The median response time was 
five months (range: 3-11 months)(19)(B).
High-dose dexamethasone is generally well tolerated and so 
interruption of treatment is avoided. The adverse events observed 
were fatigue, moodiness, flushing, headache, irritability, abdominal 
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were corticosteroid dependent. Previous corticosteroid response 
was predictive of response to splenectomy (p-value = 0.004). 
Under 10-year-old patients had a lower response to splenectomy 
than those older than 10 years old (41% versus 59% for complete 
response and 70% versus 30% for failure, respectively). All 
patients received pneumococcal vaccination at least two 
weeks before splenectomy and oral penicillin prophylaxis after 
splenectomy. Two patients had pneumococcal sepsis. Severe 
bleeding episodes occurred in 18% of patients(21)(B).
A long term follow up of 402 patients with ITP (median age 
at diagnosis: 34 years old; range: 1-84 years; 53 ≤ 16 years old 
at diagnosis; median age at splenectomy: 36 years old; range: 
6-85 years; 24 < 16 years old at splenectomy) showed that the 
surgery was performed at diagnosis in 1% (four cases), during 
follow-up without prior treatment in 3% (11 cases) and after one 
or more treatments in 96% (all received corticosteroids and 20% 
received IVIg). Indication for splenectomy was based on platelet 
count < 30 x 109/L and/or corticosteroid dependence. Complete 
response to splenectomy was observed in 66% of cases, partial 
response in 20% and 14% were refractory to splenectomy. There 
was no difference in response between patients aged ≤ 16 or > 16 
years old. After 48 months of follow up, 23% of the patients who 
achieved response presented recurrence(22)(B).
Splenectomy was performed in 90 children with chronic 
ITP (platelet count < 50 x 109/L for more than six months) when 
thrombocytopenia persisted more than six months with bleeding, 
when transitory response was obtained or the patient had important 
adverse events (headache and vomiting after IVIg, arterial 
hypertension and/or Cushing’s syndrome after corticosteroids and 
hemolysis after anti-D). Prior to splenectomy, all patients received 
IVIg (total dose 2 g/kg/day), 29 patients received anti-D (15 mg/kg/
day for three days) and 81 patients received oral prednisone (1-2 
mg/kg/day), intravenous methylprednisone (> 5 mg/kg/day) or 
dexamethasone (24 mg/m2/day for four days). Treatment response 
was defined as negative if platelet count remained below 50 x 109/L, 
as positive if the count was above this value and as a good response 
if it was > 150 x 109/L. Response to splenectomy was considered 
positive when platelet count remained stable and above 50 x 109/L 
during follow-up. There was no significant difference between 
response to splenectomy and the interval between diagnosis and 
surgery. The platelet count remained > 50 x 109/L in 75% of cases 
and improved the quality of life in 85%. Treatment responses to 
pre-splenectomy corticosteroids and IVIg classified as good or 
positive were correlated with response to splenectomy. There was 
no difference in the incidence of infections that occurred during 
follow up (0.028 patient/years) between children submitted or not 
to antibiotic prophylaxis(23)(B).
Of 696 children with ITP, 32.6% (230 patients) had chronic 
ITP (platelet count < 150 x 109/L for more than six months); 13% 
(30 cases) underwent splenectomy (mean time 2.5 ± 1.4 years 
from diagnosis). Normal platelet count was obtained in 73.3% 
(20 cases) during a mean follow-up of 58.4 ± 46.3 months (range: 
12-156). All patients received Streptococcus pneumoniae, 
Haemophilus influenzae and Neisseria meningitidis vaccines 
prior to surgery and antibiotic prophylaxis with penicillin or 
amoxicillin after splenectomy. Spontaneous remission occurred 
between six months and ten years after diagnosis in 53 (26.5%) 
of the 200 non-splenectomized children and of these 56.6% 
had remission between the 6th and 12th month after diagnosis. 
Spontaneous remission, when compared to remission induced by 
splenectomy, was more frequent in younger children (5.0 ± 3.4 
years versus 8.0 ± 4.4 years; p-value = 0.008)(24)(B).
In 134 children with ITP with a median age at diagnosis of 
9.5 years old (range: 1.1-17.6), a median age at splenectomy of 
11.8 years old (range: 2.7-20.7) and a median duration of disease 
of 1.8 years (range: 0.1-10.8), splenectomy resulted in complete 
response in 86.3% of cases, partial response in 9.2% and no 
response in 4.6%. Splenectomy was performed in 20 children with 
acute ITP (< 6 months of thrombocytopenia). Complete response 
was maintained for one year in 80% of cases. Factors associated 
with complete remission were older age [Odds ratio (OR): 1.3], 
longer duration of ITP (OR: 2.0) and male gender (OR: 3.1)(12)(B).
Splenectomy was indicated for 19 children with chronic ITP 
(mean age: 12 years; range: 7-17 years) with a mean time between 
diagnosis and surgery of 32 months (range: 3.5-120) because of 
bleeding refractory to therapy (corticosteroids, anti-D, IVIg or 
rituximab) and contraindication to medication. After splenectomy, 
68% of children achieved complete response, 16% partial response 
and 16% did not respond to surgery. There was no correlation 
between initial response to treatment before splenectomy (anti-D, 
IVIg or rituximab) and response to splenectomy. However there 
may be a correlation between the absence or presence of response 
to preoperative corticosteroids and complete postoperative 
response (100% and 50%, respectively)(25)(B).
In 37 splenectomized children with chronic ITP, 20 had had 
complete response to corticosteroids. Of these, 80% achieved 
complete response to splenectomy. The surgery was successful 
in 75% of the eight patients who did not have any response to 
corticosteroid therapy. These findings suggest that there is no 
correlation between previous response to corticosteroids and 
response to splenectomy(26)(B).
Recommendation: Splenectomy in children may be indicated in 
cases of chronic ITP refractory to drug treatment with recurrent 
bleeding. This may determine the hematologic response (complete 
or partial) in up to 80% of cases.
Is there evidence of predictive clinical or laboratory 
criteria of response to splenectomy in primary immune 
thrombocytopenia?
In 32 patients aged six months to 17 years diagnosed with 
ITP (platelet count < 20 x 109/L) treatment response to IVIg and 
splenectomy was defined as excellent (platelet count > 150 x 109/L 
in one week), good (platelet count between 50 x 109/L and 149 x 
109/L) or poor (platelet count < 50 x 109/L). Patients with good 
or excellent responses to IVIg (95%) had an excellent response to 
splenectomy. IVIg response had sensitivity, specificity, positive 
and negative predictive values of 91%, 66%, 87% and 75%, 
respectively in predicting response to splenectomy. Corticosteroid 
treatment and time between diagnosis and splenectomy did not 
correlate with response to splenectomy(27)(B).
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In an Italian study with 90 children, splenectomy was 
performed in patients with ITP when thrombocytopenia persisted 
for more than six months after diagnosis and when there was 
bleeding, transitory therapeutic success or adverse events. 
Response to splenectomy occurred in 75% patients. Response 
to IVIg and corticosteroids before surgery was predictive of 
response to splenectomy, but the interval between diagnosis and 
surgery was not(24)(B).
An analysis of 19 patients showed that indications for 
splenectomy in children with ITP included bleeding symptoms 
refractory to treatment and drug contraindication. After splenectomy, 
70% of patients had complete response (mean platelet count: 399 x 
109/L ± 173 x 109/L), 20% partial response (mean platelet count: 64 
x 109/L ± 19 x 109/L) and 10% no response (mean platelet count: 20 
x 109/L ± 20 x 109/L). There was no correlation between response 
to splenectomy and anti-D, IVIg or rituximab response. Using a 
platelet count of 100 x 109/L as a cut-off point, the preoperative 
hematological response to corticosteroids was predictive of 
response to splenectomy. In this population there was an inverse 
relationship between the platelet count with corticosteroids and the 
platelet count after splenectomy(25)(B).
In a study published in 2011 on 37 patients with ITP followed 
up for ten years, there was no significant difference between the 
response to splenectomy and age (the age at diagnosis was 10 
± 5 years old and the age at splenectomy was 12 ± 4 years old). 
In this group, complete response to splenectomy (mean platelet 
count 324 x 109/L ± 147 x109/L) was found in 84% and partial 
response (mean platelet count 104 x 109/L ± 29 x 109/L) in 16%. 
There was no association between the patients’ response to IVIg, 
anti-D or rituximab and response to splenectomy (p-value = 
0.24). There was a correlation between corticosteroid response 
and the response to splenectomy(26)(B).
Recommendation: The immediate preoperative and postoperative 
platelet counts and the preoperative response to corticosteroids 
and IVIg are predictors of response to splenectomy.
Is there indication for vaccination in patients who will 
be submitted to splenectomy? Which vaccines are 
indicated?
In a study of 264 patients splenectomized due to different 
underlying diseases, the mean age was 8.5 ± 4.5 years old. 
Comparing the ages between children with infection (positive 
blood culture for encapsulated bacteria) and without infection, 
those with no infection (96%) were older than those with infection 
(mean age at surgery 8.7 ± 4.4 years versus 3.0 ± 2.6 years; 
p-value < 0.0001). Infections occurred four days to 9.7 years after 
splenectomy, with patient age ranging from eight months to 14.4 
years. The infection and mortality rates were 3.8% and 0.4%, 
respectively. Higher rates of infection (13.8% versus 0.5%) and 
mortality (1.5% versus 0%) were found in patients of up to five 
years old at the time of splenectomy compared to over five-year-
old children. All children received antibiotic prophylaxis and 70% 
were immunized (54% against pneumococcus and 16% against 
pneumococcus associated with H. influenzae type b). None were 
immunized against N. meningitidis. Patients with infections were 
vaccinated in, on average, two weeks before the splenectomy, 
while those who did not have infections received the vaccine 
on average 4.5 months before, suggesting that the time between 
vaccination and surgery is important. Thus, early pneumococcal 
immunization is associated to lower risk of infection and the 
preoperative immunization is associated to lower risk of severe 
infections compared to postoperative immunization (2.6% versus 
7.1%). Infections in immunized patients occurred on average 
2.1 years (median 5.5 months) after splenectomy, while the non-
immunized patients had infections on average two weeks (median 
two weeks) after the surgery. About 77% of infections occurred 
before five years after splenectomy (recommended period for 
revaccination). None of the revaccinated patients presented 
infections. The incidence of infection and mortality reduced by 
47% and 88%, respectively with prophylaxis(28)(B).
Of the asplenic children (12 with congenital asplenia and ten 
with surgical splenectomy, including three with ITP), 75% received 
the 23-valent pneumococcal polysaccharide vaccine and 82% received 
antibiotic prophylaxis. In this group, the incidence of invasive infection 
caused by S. pneumoniae was 1.5%. Clinical manifestations included 
bacteremia, meningitis, bacteremia with acute otitis media or sinusitis 
or pneumonia and meningitis with osteomyelitis, with a mortality of 
27% (six patients, all with meningitis)(29)(C).
After splenectomy in 538 patients (15 patients under 15 years 
old; 96 with hematological diseases), the incidence of bacteremia 
was 2.3 per 100 person-years at risk, 45% of cases within 30 days 
after surgery and only one case of S. pneumoniae (in an adult). 
No case of bacteremia or cases of N. meningitidis or H. influenzae 
type b were observed in under 15-year-old children. All children 
had received pneumococcal vaccines, while only 59% of adults 
had been vaccinated. There is evidence that pneumococcal 
vaccine reduces the risk of postoperative bacteremia(30)(B).
In a retrospective study of 33 pediatric patients with 
chronic ITP (> 6 months of thrombocytopenia), splenectomy was 
indicated in persistent severe thrombocytopenia (platelet count < 
10 x 109/L) with purpura and epistaxis, menorrhagia or recurrent 
bleeding (hematuria, melena, etc.). Pneumococcal vaccine had 
been administered in 75% of cases, most preoperatively, and 40% 
had also been immunized for N. meningitidis. Some patients were 
not on penicillin prophylaxis. After 25 years of follow up, there 
was only one death by infection (mortality rate of 3.1%), while 
the other patients showed no bacterial infections(31)(C).
In a study of 134 splenectomized children with ITP, 84.3% 
were vaccinated about 30 days before splenectomy while 15.7% 
did not receive vaccinations. Considering the vaccinated group, 
82.8% of vaccinations were against S. pneumoniae, 50.8% 
against H. influenzae type b and 48.5% against N. meningitidis. 
Fever without sepsis occurred postoperatively in 9.7% of patients 
and less than 1% had postoperative sepsis. Antibiotic prophylaxis 
(mostly with penicillin) was given to 94% of patients. During a 
period of 225.2 patient-years, the risk of sepsis was 0.031 per 
patient-year, without deaths. Of the patients who developed 
sepsis, only one patient had not received a vaccination(12)(C). 
In splenectomized patients (48.3% ≤ 16 years old and 51.7% 
adults) for different indications, invasive infections occurred in 
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3.2% of cases with an overall mortality rate of 1.4%. The mean 
time of follow up was 6.9 years. The incidence of infection 
among children and adults was similar, but mortality was 
higher in children (1.7%) versus adults (1.3%; p-value < 0.001). 
The incidences of infection were higher among patients with 
thalassemia major (8.2%) and sickle cell anemia (7.3%; p-value 
< 0.01), while the lowest incidences were found in patients with 
ITP (2.1%) and trauma (2.3%). The highest mortality rates were 
observed for patients with thalassemia major (5.1%) and sickle 
cell anemia (4.8%; p-value < 0.01) and the lowest were observed 
in patients splenectomized for trauma (1.1%), ITP (1.2%) and 
spherocytosis (1.3%; p-value < 0.00001). Considering only the 
194 children with ITP, the incidence of infection was 2.6% and 
the mortality rate was 1.5%. Among the 358 cases with identified 
etiologic agents, streptococcal pneumonia was the most common 
infection (66%) with 55.3% of mortality. The highest mortality 
rate however was attributed to gram-negative bacteria (62%) and 
N. meningitidis (58.8%; p-value = 0.017)(32)(B).
Patients splenectomized due to ITP (n = 196), hypersplenism (n 
= 78), non-Hodgkin lymphoma (n = 89), hemolytic anemia (n = 55), 
Hodgkin’s disease (n = 9) and without pre-existing hematological 
disease (n = 452) were evaluated for response to the 23-valent 
pneumococcal polysaccharide vaccine and trivalent inactivated 
influenza vaccine. Initially the heptavalent pneumococcal conjugate 
vaccine was used and then the 23-valent pneumococcal vaccine. Of 
all of the patients, 72% were adults and 28% were children (< 18 
years old). At the time of splenectomy, 92.6% were over 18 years 
old and 7.4% were children. Sixty-one percent of the ITP cases 
were under 18 years old. The main indication for splenectomy in 
adults and children was ITP (4.04 splenectomies/1000 person-years). 
Immunization against S. pneumoniae was performed in 16.5% of the 
splenectomized patients (21.4% for ITP cases) and immunization 
against influenza in 53.1% of the patients (62.8% for ITP cases). 
Infection episodes are more common in splenectomized rather 
than in non-splenectomized patients (151 visits/100 person-years 
versus 120 visits/100 person-years; p-value < 0.0001). The risk of 
death to splenectomized patients due to hematological diseases is 
significantly higher when compared to non-splenectomized patients 
[individual analysis of ITP patients shows Hazard Ratio (HR): 1.57; 
95% CI: 1.08-2.29]. For splenectomized patients, pneumococcal 
immunization was associated with decreased risk of death when 
the effect of the influenza vaccine was not considered (HR: 0.68; 
95% CI: 0.47-1.00). However, no benefit was observed with the 
pneumococcal vaccine after adjusting for the effect of the influenza 
vaccine (HR: 7.1; 95% CI: 0.70-1.65). The risk of death decreased 
by 54% for all asplenic patients who received the influenza vaccine, 
including the subgroup of patients with ITP(33)(B).
The immune response of 20 asplenic patients (16 
splenectomized and four with congenital asplenism - none with 
ITP) aged between five and 25 years old (mean: 14.7 years) to a 
dose of H. influenzae type b conjugate vaccine demonstrated that 
the geometric mean antibody concentration prior to vaccination 
(3.21 mg/mL) rose significantly after vaccination to 6.78 mg/
mL. At 4.5 years after vaccination the geometric mean antibody 
concentration was similar to that of unvaccinated children. The H. 
influenzae type b conjugate vaccine provides extended protection 
in asplenic patients(34)(B).
One study compared splenectomized patients who received 
pneumococcal vaccines and developed severe pneumococcal 
infections with non-splenectomized patients who were also 
vaccinated with pneumococcal vaccines and developed severe 
pneumococcal infections. Splenectomy was performed in patients 
with Hodgkin’s disease, ITP, hemolytic anemia and trauma. 
Of the 33 splenectomized patients, 48.4% had pneumococcal 
sepsis, 21.2% pneumococcal meningitis and 30.3% had both 
infections. All patients received 12- or 14-valent pneumococcal 
vaccines. Considering the pneumococcal serotypes isolated in 
the infections, 63.3% were included in the vaccine, in particular 
the 6A, 14, 19F and 23F serotypes. The most common serotype 
not included in the vaccine was 22F. The mean interval 
between pneumococcal vaccine and pneumococcal infection 
was ten months for serotypes included in the vaccine and 6.7 
months for serotypes not included. Comparatively, of the 22 
non-splenectomized patients who had received pneumococcal 
vaccinations (sickle cell anemia, hematological malignancies 
and diseases that impaired the immunological system), 59% 
had pneumonia due to S. pneumoniae, 27.2% had sepsis and 
13.6% meningitis. A pneumococcal serotype was a vaccine type 
in 63.6% of cases and non-vaccine serotypes in 36.3% of cases. 
The most common serotypes isolated related to the vaccine 
were 6A, 19F and 23F, and those isolated unrelated to vaccine 
were 6B and 19A. The mean interval between vaccination and 
pneumococcal infection was 7.4 months(35)(B).
In an epidemiological study published in 1997 of 149 patients 
(14 patients under 15 years old), the indications for splenectomy were 
hematological diseases (27%), trauma (33%), incidental (12%), 
accidental (20%) and others (8%). Of the children who received 
pneumococcal vaccinations, 35.7% had received it within the five 
years preceding splenectomy. Based on the anti-pneumococcal 
antibody titers, revaccination was required in one case (20%) in the 
immunized group less than five years before surgery and in 63% 
(five patients) in the group that had been immunized more than 
five years before surgery. A presumed protective level of antibodies 
was found in 52% of the immunized patients. The mean interval 
between splenectomy and the pneumococcal vaccination was 23 ± 
8 days when given before splenectomy and 78 ± 3 days when given 
after splenectomy. In relation to H. influenzae type b vaccine, two 
children (1%) and 59 adults (40%) required revaccination. Thus, it 
was observed that 37% of the 149 splenectomized patients after ten 
years of follow up were still protected both for S. pneumoniae and 
for H. influenzae type b(36)(B).
Recommendation: Due to increased risk of infections by S. 
pneumoniae in splenectomized patients, both children and adults, 
the pneumococcal vaccine is indicated and should be performed 
before splenectomy. Immunization against other encapsulated 
agents such as H. influenzae type b and N. meningitidis should 
also be performed at least 14 days before splenectomy. An annual 
vaccination against the influenza virus is also recommended.
Is there indication of penicillin prophylaxis after 
splenectomy?
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Functional or anatomical asplenia is associated with a higher 
risk of severe bacterial infection or sepsis after splenectomy by 
encapsulated germs. There are no specific studies for ITP in relation 
to the need for prevention of these infections. Thus, recommendations 
for the use of penicillin prophylaxis in splenectomized patients with 
ITP are based on experience in children with sickle cell disease. As 
pneumococcal vaccines do not protect completely against infections, 
antibiotic prophylaxis has been recommended regardless of the 
vaccination status(37)(B)(38-42)(D).
The need for antibiotic prophylaxis using oral or intramuscular 
penicillin in patients with sickle cell disease and functional asplenia 
is already well established due to the risk of invasive infections by 
S. pneumoniae(43-45)(A). A multicenter, randomized, double-blind, 
placebo-controlled trial showed that oral penicillin V prophylaxis 
daily (125 mg twice a day) reduces the incidence of sepsis by S. 
pneumoniae in children with sickle cell disease who begin treatment 
before the age of three years. The trial was terminated eight months 
early, after a mean of 15 months of follow-up, because there was 
an 84% reduction in the incidence of severe bacterial infection in 
the group treated with penicillin compared with the placebo group 
(p-value = 0.0025)(44)(A).
Little evidence exists in cases of splenectomized patients, 
but it has already been observed that the incidence of infections 
and mortality in splenectomized children decreased by 47% 
and 88%, respectively with antibiotic prophylaxis and with 
immunization(28)(B).
A retrospective study in Denmark between 1969 and 1978 
evaluated 456 under 15-year-old splenectomized children, 
52 of whom had ITP followed up on average for 6.2 years. 
In ITP, 11.5% of post-splenectomy infections (meningitis or 
pneumococcal bacteremia) were observed with 50% mortality. 
Under 4-year-old patients had a higher probability to develop 
infection after splenectomy. These data suggest the need for 
pneumococcal vaccines and antibiotic prophylaxis with penicillin 
for splenectomized children(29)(B).
In a group of 318 splenectomized patients aged ten and 
26 years old, 118 of whom had chronic ITP (> 6 months of 
thrombocytopenia), overwhelming infections were observed in 
5.7% of the cases, 56% of which occurred within six months of 
the splenectomy. About 60% of the patients were on oral penicillin 
prophylaxis. The prevalence of overwhelming infections after 
splenectomy in patients who had more knowledge about the risk 
of sepsis was lower than in those who understood less (1.4% versus 
16.5%, respectively; p-value < 0.001). Comparing the prevalence 
among patients on regular and irregular oral penicillin prophylaxis, 
overwhelming infections after splenectomy occurred in 2.7 and 
10%, respectively (p-value < 0.01). The incidence of overwhelming 
infections after splenectomy in patients who received pneumococcal 
vaccines decreased from 7.3% to 3.2% (p-value < 0.05). These data 
reinforce the importance of proper guidance about oral penicillin 
prophylaxis and pneumococcal vaccines for splenectomized 
patients, regardless of the underlying disease(46)(B).
In a study of 40 patients with overwhelming infections 
after splenectomy aged 18 months and 85 years old, the interval 
between splenectomy and infection ranged from 24 days to 59 
years (60% of cases between ten and 30 years). Overwhelming 
infections were more frequent in patients aged 30-49 years old. 
The main reason for splenectomy was trauma (13 cases), followed 
by Hodgkin’s lymphoma (eight cases), ITP (six cases), hemolytic 
anemia (five cases), injury in abdominal surgery (four cases), 
chronic lymphocytic leukemia, chronic granulomatous disease and 
myelofibrosis with thrombocytopenia associated with systemic 
lupus erythematosus (one case each). The mortality rate due to 
infection was 45% (19 patients). Thirty-one cases of pneumococcal 
pneumonia and six cases of pneumococcal meningitis without 
sepsis were diagnosed, totalizing 37 infection episodes (88%) due 
to S. pneumoniae. Another five cases of sepsis were by Klebsiella 
pneumoniae, Escherichia coli and Salmonella typhimurium. Only 
12 patients had received pneumococcal vaccinations and ten of 
these suffered pneumococcal infections; at least four had possible 
vaccine failures. The pneumococcal vaccine used was the 23-valent 
which contains 85% of the strains found in the infections. Only 
22% were on antibiotic prophylaxis. This study confirmed that the 
higher risk of overwhelming infections after splenectomy does not 
only occur in the first years after surgery, but that this risk remains 
for years(37)(B). Thus, it is important always to be alert for febrile 
episodes in splenectomized patients.
Despite its potential advantage of saving lives, there are 
some issues in relation to oral antibiotic prophylaxis, including 
patient compliance, the optimal duration of treatment and the 
effect of prophylaxis on the development of pneumococcal 
resistance to penicillin. Compliance to antibiotic treatment is 
highly variable and often sub-optimal, even with educational 
reinforcement about the importance of antibiotic prophylaxis in 
the population(46-49)(B). The age at which antibiotic prophylaxis 
is stopped is often an empirical decision. Children with sickle 
cell disease without previous severe pneumococcal infections 
or surgical splenectomy and with appropriate clinical follow-
up may stop penicillin prophylaxis at five years old(45)(A). 
However, there is no consensus on the appropriate age to 
discontinue antibiotic prophylaxis. The Canadian Pediatric 
Society recommends that the discontinuation of antimicrobial 
prophylaxis in asplenic or hyposplenic patients is five years old 
or one year after splenectomy or depending on patients’ clinical 
characteristics(38)(D). The American Academy of Pediatrics 
indicates discontinuation at five years old as long as the patient 
has not presented with any invasive pneumococcal infection 
and has completed the vaccination scheme(39)(D). The British 
Committee for Standards in Hematology suggests prophylaxis 
mainly during the first two years after splenectomy for all patients 
up to 16 years old and when there is involvement of the immune 
function(40)(D). Continuous prophylaxis may increase the risk of 
strains resistant to antibiotics. Penicillin resistance was observed 
in children with repeated cycles of acute otitis media treatment(50)
(D). In patients with sickle cell disease on penicillin prophylaxis, 
penicillin-resistant of pneumococcal strains were found in the 
oropharynx, associated with penicillin use(51)(A) or not(52)(B)(53)
(A). A Brazilian study showed that, in children with sickle cell 
anemia on penicillin prophylaxis who had received the 7-valent 
pneumococcal vaccine, the prevalence of nasopharyngeal 
colonization by pneumococcal bacteria was 17% versus 11% in 
a control group of healthy children. The prevalence of penicillin-
resistant strains was 57.5% in the patients with sickle cell disease 
and 25% in the control group(54)(A).
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Apart from pneumococcus, invasive infections by H. influenzae 
or by N. meningitidis are also considered important in splenectomized 
patients. Therefore, these patients should be vaccinated before surgery. 
If the splenectomized patient has direct or indirect contact with 
patients with invasive infections by these agents, the same prophylaxis 
proposed for non-splenectomized individuals should be provided 
using rifampicin (10 mg/kg twice/day for four doses - maximum 600 
mg each dose) or, if the patient is less than one month old, 5 mg/kg 
twice/day for four doses. Alternative prophylaxis can be made  with 
ceftriaxone (125 mg) single dose for under 12-year-old children, 
ceftriaxone (250 mg) single dose for over 12-year-old children or 
ciprofloxacin (500 mg) single dose for adults. As prophylaxis reduces 
the risk of infection but not of invasive disease, splenectomized 
patients should be carefully evaluated in the event of fever(41)(D).
Although the effectiveness of prophylactic antibiotics has been 
proven only in children with sickle cell disease, it is recommended 
that all children with asplenia or splenectomy receive prophylactic 
antibiotics. Several consensus guidelines recommend that patients 
and family members should be advised about the risks of infection 
in splenectomized patients, on vaccinations against pneumococcus, 
meningococcus, H. influenzae type b and influenza virus (annual) 
and on prophylactic antibiotics in under 5-year-old children and 
for at least one year after surgery. The maintenance of prophylaxis 
will depend on the individual characteristics of each patient(37)(B)
(38-42)(D). However, the pneumococcal polyvalent vaccine, the H. 
influenzae type b conjugate vaccine and the antibiotic prophylaxis 
reduce, but do not eliminate the risk of sepsis in children with 
sickle cell disease(55)(B). Therefore, despite the use of prophylaxis 
and vaccines, patients should be monitored for febrile episodes and 
receive antibiotics for suspected bacterial infections(37)(B)(38-42)(D).
The most widely used antibiotic for prophylaxis against 
infections by pneumococcus is penicillin. The daily dose of oral 
penicillin V is 125 mg twice per day in under 3-year-old children, 250 
mg twice per day in over 3-year-old children and 500 mg twice per day 
in adults. Children who have not suffered any invasive pneumococcal 
infection and have completed the vaccine schedule for pneumococcus 
can stop prophylaxis at five years old(38,39,41)(D)(44-45)(A). If the option 
is penicillin G benzathine, the dose in children under 27 kg is 600,000 
IU every three weeks and for weight > 27 kg, the dose is 1,200,000 
IU every three weeks(41)(D). As an alternative to penicillin, in cases 
of hypersensitivity, erythromycin is used at a dose of 250-500 mg per 
day in adults and over 8-year-old children, 250 mg/day in patients 
aged 2-8 years old and 125 mg/day in under 2-year-old children(41)
(D). There are no randomized studies to evaluate the effectiveness 
of amoxicillin as a prophylactic antibiotic in patients with sickle cell 
disease or in splenectomized patients, but it may be an option in cases 
of pneumococcal resistance to penicillin(38)(D).
Recommendation: The use of penicillin prophylaxis in 
splenectomized patients with ITP is indicated based on experience 
with children with asplenia or sickle cell disease who are at 
increased lifelong risk for sepsis and severe infections, especially 
in the first years after splenectomy. The vaccination scheme against 
encapsulated germs (pneumococcus, meningococcus and H. 
influenzae type b) and the administration of oral penicillin V daily or 
penicillin G benzathine every three weeks for at least two years after 
splenectomy are recommended to significantly reduce the risk of 
infections in this population. It should be noted that the patient may 
present infections after discontinuation of antibiotic prophylaxis. 
Regarding the dose of oral penicillin V, 125 mg = 200,000 IU, 250 
mg = 400,000 IU, and 500 mg = 800,000 IU(56)(D).
Is there evidence that rituximab benefits patients with 
immune thrombocytopenia? In which situations is rituximab 
recommended?
A systematic literature review of refractory ITP (newly 
diagnosed or chronic) in under 18-year-old patients included 
14 studies (including several case reports and one longitudinal 
observational study) with 312 patients, all with platelet counts 
of less than 50 x 109/L. The treatment of choice was intravenous 
rituximab and efficacy analysis was performed on studies with more 
than five patients. About 10% of patients had been splenectomized. 
Pooled data showed that response rate (platelet count ≥ 30 x 
109/L) and complete response rate (platelet count ≥ 100 x109/L) 
to rituximab were, respectively, 68% and 39%. Pooled analyses 
of data from 14 studies with 243 patients showed that the median 
times to obtain response and of response duration were three 
weeks and 12.8 months, respectively. At the time of analysis of the 
median duration of response, 56.5% of the patients maintained the 
response to treatment with rituximab. It is important to note that 
there was significant heterogeneity between the studies(57)(C).
Of the 190 patients reported in 11 studies with more than 
five patients, 41.1% had adverse events. Most of the adverse 
events (84.7%) observed in 23 studies were mild to moderate 
with the most frequent being allergic reactions (pruritus, urticaria, 
chills and fever). Serum sickness (fever, rash, arthralgia and 
fatigue) after one or two doses of rituximab, infections (varicella, 
pneumonia, enteroviral meningoencephalitis), prolonged 
hypogammaglobulinemia leading to increased susceptibility to 
infections were also described. No death has been reported(57)(C).
Recommendation: Treatment with rituximab in patients with ITP 
unresponsive to conventional treatment can produce a response 
(complete or partial) but adverse events may occur. However, 
randomized studies with rituximab are required to evaluate its 
efficacy and safety in children and adolescents with refractory ITP.
What is the platelet level to indicate treatment and which is 
the therapeutic option in newborns of mothers with primary 
immune thrombocytopenia?
Evaluation of 32 newborns of 29 pregnant women with 
ITP showed that seven neonates (21.8%) were born with platelet 
counts ≤ 50 x 109/L. Three newborns with clinical manifestations 
had platelet counts of less than 15 x 109/L and skin bleeding, 
umbilical cord bleeding or gastric bleeding; all received IVIg 
and prednisone, as well as platelet transfusions in cases of more 
important hemorrhages. All children with platelet counts ≤ 50 x 
109/L received IVIg and prednisone(58)(C).
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In 39 pregnant women with ITP, thrombocytopenia ≤ 53 
x 109/L was observed in 16% of the newborns but there were 
no cases of death or intracranial hemorrhage. All these neonates 
received IVIg, combined or not with corticosteroids and/or 
platelet transfusions(59)(C).
On reviewing 15 children born to mothers with ITP 
during a follow up period of ten years, the incidence of severe 
thrombocytopenia (< 50 x 109/L) was 20%, with no intracranial 
hemorrhage, seizures or other complications in the newborns. 
No child required treatment with corticosteroids, IVIg or platelet 
transfusions(60)(C).
Evaluating 46 neonates of mothers with ITP diagnosed 
before or during pregnancy, eleven (23.9%) infants were born 
thrombocytopenic. Of these, three had platelet counts of less than 30 
x 109/L, five had platelet counts between 30 x 109/L and 99 x 109/L 
and three had platelet counts between 100 x 109/L and 149 x 109/L. 
No severe bleeding was reported. Five newborns (10.8%) presented 
hemorrhage symptoms at birth: two (4.3%) had thrombocytopenia 
(53 x 109/L and 50 x 109/L) and hematuria (n = 1) or petechiae and 
cephalohematoma (n = 1); three (6.5%), despite normal platelet 
counts at birth, had petechiae and one also had cephalohematoma. 
Due the potential risk of bleeding, three patients with platelet counts 
≤ 30 x 109/L received IVIg (1 g/kg/day) for two days, with adequate 
responses in eight, eight and 42 days after treatment(61)(C).
Another investigation studied 13 pregnant women (one 
twin) with ITP, and only one newborn (7.1%) presented 
thrombocytopenia (50 x 109/L) at delivery, without the need 
for treatment. There were two (14.2%) fetal deaths without 
signs of bleeding and morphologically normal. None of the 
children showed clinical signs of hemorrhage or other neonatal 
complications(62)(C).
Clinical and laboratory characteristics of 29 newborns of 29 
pregnant women diagnosed with ITP were evaluated. Fourteen 
neonates (48%) had platelet counts of less than 150 x 109/L and 
of these, 50% had less than 50 x 109/L, 28.5% between 50 x 109/L 
and 99 x 109/L and 21.5% between 100 x 109/L and 149 x 109/L. 
Mucosal and/or gastrointestinal bleeding was reported in 17% 
(n = 5) of the newborns. Transfusion was necessary in two 
neonates (6.9%) with gastrointestinal bleeding with platelet 
counts of 9 x 109/L and 19 x 109/L, respectively who received 
IVIg (1 g/kg/day) for two days and prednisolone (2 mg/kg/day). All 
newborns with platelet counts less than 100 x 109/L (78.5%, n = 11) 
received IVIg, even when there was no associated bleeding(63)(C).
In a retrospective analysis of 130 newborns of 127 
pregnancies of 88 women diagnosed with ITP, 15.4% showed 
platelet counts below 100 x 109/L, 8.5% below 50 x 109/L and 
2.3% below 20 x 109/L. Treatment at birth with prednisolone, 
IVIg and/or platelet transfusions was performed in 3.8% of these 
newborns. Only one fetus had an intracranial hemorrhage, but it 
was intrauterine(64)(C). In this article there is no report of platelet 
levels in which treatment was indicated.
Recommendations: In the absence of bleeding, there is no 
defined value in relation to the ideal platelet count to indicate 
treatment in newborns of mothers with ITP. It is recommended 
to treat newborns with platelet count ≤ 50 x 109/L and, in 
cases of platelet counts between ≤ 50 x 109/L and 100 x 109/L, 
start treatment only in the presence of bleeding. Intravenous 
immunoglobulin is the treatment most commonly used.
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